Literature DB >> 7812966

NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells.

S S Pan1, G L Forrest, S A Akman, L T Hu.   

Abstract

An association between the resistance to mitomycin C (MMC) and a decrease of NAD(P)H:quinone oxidoreductase (NQO1) activity was reported for a MMC-resistant subline, HCT 116-R30A, derived from MMC-sensitive HCT 116 cells. Eight NQO1 cDNA clones were isolated from these two sublines by reverse transcription-PCR. Two clones, pDT9 from HCT 116 and pDT20 from HCT 116-R30A, are the full length of 274 amino acids. These two clones differ by a T to C substitution at nucleotide 464, which results in a replacement of arginine 139 by tryptophan in the enzyme. NQO1 of pDT9 and pDT20 was expressed in Escherichia coli, purified, and shown to have a protein subunit of M(r) 30,000. The change of amino acid 139 resulted in a shift of isoelectric pH from 9.5 to 8.35 and a 60% decrease of activity in reducing MMC. All of the other six clones differ from pDT9 by a deletion of exon 4. On Northern blot, we detected two mRNA species of NQO1 (1.2 and 2.7 kilobases) due to alternative polyadenylation in all sublines. MMC-resistant sublines showed 75-90% mRNA expression relative to HCT 116 cells. Reverse transcription-PCR amplification of cDNA fragment of nucleotide 298-617 revealed two full-length mRNAs in HCT 116 cells but only one full-length mRNA in HCT 116-R30A cells. An exon 4 deletion mRNA was detected in both sublines. The two full-length mRNAs may be from either alleles or chimeras of the same gene and the exon 4 deletion mRNA is a result of alternative splicing. On Western blot, we detected only one M(r) 30,000 protein in all sublines. A substantial decrease of this protein in MMC-resistant sublines (5% of HCT 116) explained the 95% decrease of their NQO1 activity. Transcriptional regulation and posttranscriptional modification may be responsible for the disparity of gene expression of NQO1 and the low concentration of NQO1 protein in MMC-resistant sublines. Reversal of MMC resistance and the recovery of NQO1 in two revertants further supports the hypothesis that cellular control of NQO1 can modulate the cytotoxicity of MMC.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7812966

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

Review 1.  3' end mRNA processing: molecular mechanisms and implications for health and disease.

Authors:  Sven Danckwardt; Matthias W Hentze; Andreas E Kulozik
Journal:  EMBO J       Date:  2008-02-06       Impact factor: 11.598

Review 2.  Alternative poly(A) site selection in complex transcription units: means to an end?

Authors:  G Edwalds-Gilbert; K L Veraldi; C Milcarek
Journal:  Nucleic Acids Res       Date:  1997-07-01       Impact factor: 16.971

3.  Enhancement of the efficacy of mitomycin C-mediated apoptosis in human colon cancer cells with RNAi-based thioredoxin reductase 1 deficiency.

Authors:  Preeyaporn Koedrith; Young Rok Seo
Journal:  Exp Ther Med       Date:  2011-06-30       Impact factor: 2.447

4.  Relationships between metabolic and non-metabolic susceptibility factors in benzene toxicity.

Authors:  David Ross; Hongfei Zhou
Journal:  Chem Biol Interact       Date:  2009-11-24       Impact factor: 5.192

5.  NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphisms imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells.

Authors:  Seema Singh; Muhammad Zahid; Muhammad Saeed; Nilesh W Gaikwad; Jane L Meza; Ercole L Cavalieri; Eleanor G Rogan; Dhrubajyoti Chakravarti
Journal:  J Steroid Biochem Mol Biol       Date:  2009-07-21       Impact factor: 4.292

6.  Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans.

Authors:  Adam Bress; Shitalben R Patel; Minoli A Perera; Richard T Campbell; Rick A Kittles; Larisa H Cavallari
Journal:  Pharmacogenomics       Date:  2012-12       Impact factor: 2.533

Review 7.  NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis.

Authors:  Neela Guha; Jeffrey S Chang; Anand P Chokkalingam; Joseph L Wiemels; Martyn T Smith; Patricia A Buffler
Journal:  Am J Epidemiol       Date:  2008-10-22       Impact factor: 4.897

Review 8.  Challenges identifying genetic determinants of pediatric cancers--the childhood leukemia experience.

Authors:  Daniel Sinnett; Damian Labuda; Maja Krajinovic
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

Review 9.  Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family.

Authors:  Vasilis Vasiliou; David Ross; Daniel W Nebert
Journal:  Hum Genomics       Date:  2006-03       Impact factor: 4.639

10.  Genetic polymorphism 609C>T in NAD(P)H:quinone oxidoreductase 1 enhances the risk of proximal colon cancer.

Authors:  Jolien J M Freriksen; Jody Salomon; Hennie M J Roelofs; Rene H M Te Morsche; Jos W J van der Stappen; Polat Dura; Ben J M Witteman; Martin Lacko; Wilbert H M Peters
Journal:  J Hum Genet       Date:  2014-05-15       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.